GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (NAS:PRQR) » Definitions » Shiller PE Ratio

ProQR Therapeutics NV (ProQR Therapeutics NV) Shiller PE Ratio : (As of May. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is ProQR Therapeutics NV Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ProQR Therapeutics NV Shiller PE Ratio Historical Data

The historical data trend for ProQR Therapeutics NV's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV Shiller PE Ratio Chart

ProQR Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ProQR Therapeutics NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ProQR Therapeutics NV's Shiller PE Ratio

For the Biotechnology subindustry, ProQR Therapeutics NV's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Shiller PE Ratio falls into.



ProQR Therapeutics NV Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ProQR Therapeutics NV's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, ProQR Therapeutics NV's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.098/128.5800*128.5800
=-0.098

Current CPI (Mar. 2024) = 128.5800.

ProQR Therapeutics NV Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.311 99.240 -0.403
201409 -0.554 99.960 -0.713
201412 -0.111 99.050 -0.144
201503 0.011 99.750 0.014
201506 -0.415 100.230 -0.532
201509 -0.303 100.500 -0.388
201512 -0.283 99.730 -0.365
201603 -0.490 100.310 -0.628
201606 -0.483 100.260 -0.619
201609 -0.483 100.570 -0.618
201612 -0.401 100.710 -0.512
201703 -0.481 101.440 -0.610
201706 -0.528 101.370 -0.670
201709 -0.501 102.030 -0.631
201712 -0.462 101.970 -0.583
201803 -0.407 102.470 -0.511
201806 -0.269 103.100 -0.335
201809 -0.210 103.950 -0.260
201812 -0.375 103.970 -0.464
201903 -0.407 105.370 -0.497
201906 -0.339 105.840 -0.412
201909 -0.341 106.700 -0.411
201912 -0.433 106.800 -0.521
202003 -0.354 106.850 -0.426
202006 -0.090 107.510 -0.108
202009 -0.306 107.880 -0.365
202012 -0.316 107.850 -0.377
202103 -0.298 108.870 -0.352
202106 -0.289 109.670 -0.339
202109 -0.259 110.790 -0.301
202112 -0.294 114.010 -0.332
202203 -0.220 119.460 -0.237
202206 -0.201 119.050 -0.217
202209 -0.327 126.890 -0.331
202212 -0.191 124.940 -0.197
202303 -0.118 124.720 -0.122
202306 -0.108 125.830 -0.110
202309 -0.075 127.160 -0.076
202312 -0.076 126.450 -0.077
202403 -0.098 128.580 -0.098

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ProQR Therapeutics NV  (NAS:PRQR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


ProQR Therapeutics NV Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ProQR Therapeutics NV (ProQR Therapeutics NV) Business Description

Traded in Other Exchanges
Address
Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.